Crinetics Pharmaceuticals, Inc. (CRNX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 64.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-02-26

• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 64.00%, a 4.48% decline year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 66.00%, a 3.13% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 66.00%, a 1.54% increase year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 67.00%, a 0.00% change year-over-year.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 64.00%, a 3.03% decline from fiscal 2024.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 66.00%, a 0.00% change from fiscal 2023.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 66.00%, a 25.00% decline from fiscal 2022.
• Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 88.00%.